EU IVD (in vitro diagnostic) market growth slows:
This article was originally published in Clinica
Executive Summary
An analysis of the IVD markets of 14 European countries by the European Diagnostic Manufacturers Association in its just-released market statistics for 2003 shows an overall growth rate of 5.6%, although this varies enormously between countries and categories, with some sectors experiencing a decrease in sales. The statistics, which will be reviewed in more detail in next week's Clinica, are based on data supplied by Germany, Italy, France, Spain, the UK, Belgium, Switzerland, the Netherlands, Portugal, Austria, Greece, Poland, Romania and Finland. They show that the average growth rate for 2002-03 is less than that of the previous year, which was estimated to be around 6%.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.